Gedeon Richter, a Hungarian drugmaker, agreed to acquire Adelaide-based Mayne Pharma Group for $604 million through a scheme of arrangement, Business News Australia reported. The $6.40 per share offer represents a 99.4% premium over the $3.21 closing price Mayne shares recorded the previous day.
Mayne shares rose to a session high of $6.04 when the deal was announced, and Yahoo Finance reported the stock surged 86%. A yet-to-be-incorporated Australian subsidiary will be the acquiring vehicle, with Richter as the Hungarian parent guaranteeing that subsidiary's obligations, giving it 100% of Mayne via the scheme. No financing condition attaches to the deal; Richter is using its own internal cash to fund the purchase in full.
Among the conditions precedent is the closing of a separate $55.5 million transaction in which Mayne sells MPI, its international segment, to Perth-based Evaris Pharma; that sale was announced on 6 November. MPI includes Mayne's contract development and manufacturing operations, its Australian and international commercial business, and the Salisbury facility in South Australia. In addition to shareholder and court approvals, the scheme must also obtain FIRB clearance and satisfy the US Hart-Scott-Rodino antitrust requirements.
Richter deputy CEO Laszlo Kovacs said Mayne's portfolio, pointing specifically to an estetrol-based contraceptive pill combining innovative elements, together with its US commercial presence offers a platform from which to deliver new treatments to American women across multiple therapeutic areas with significant unmet need. Kovacs also said Richter's offer reflects full value for Mayne shareholders.
Mayne chair Professor Bruce Robinson said the $6.40 cash consideration lets shareholders lock in value at a substantial premium to where the stock had recently been trading, and that it acknowledges the quality of Mayne's Women's Health and Dermatology/DistributeRx businesses in the US. Mayne's board gave unanimous support to the scheme, recommending a yes vote provided no superior proposal emerges and an independent expert finds the scheme to be in shareholders' best interests.
Funicular Funds at 9.82%, Bruce Mathieson at 6.46% and Trium Capital at 5.85% are Mayne's three largest shareholders; together they hold 22.14% and all three plan to vote yes absent a superior proposal. All Mayne directors plan to vote their personally held or controlled shares in favour. The indicative timetable has the scheme booklet going out to shareholders in mid-December, a scheme meeting set for late January 2027 and implementation targeted for mid to late March 2027.
Mayne Pharma shareholders will be asked to vote on the scheme at the late January meeting; if approved and implemented, they would receive $6.40 per share in cash. The three largest shareholders and all directors have stated their intention to vote in favour.
Reporting: Business News Australia, Yahoo Finance
Written by Pick & Scroll News from the reporting and documents linked above.

